Algert Global LLC Makes New $311,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Algert Global LLC has acquired a new position in Alnylam Pharmaceuticals, purchasing 1,150 shares valued at approximately $311,000.
• Executives Pushkal Garg and Jeffrey V. Poulton sold a combined total of 3,729 shares recently, indicating a significant decrease in their stock ownership.
• The biopharmaceutical company reported $0.32 EPS in its latest earnings, exceeding expectations and reflecting a 17.3% revenue growth compared to the same quarter last year.

Algert Global LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,150 shares of the biopharmaceutical company's stock, valued at approximately $311,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. American Century Companies Inc. raised its stake in Alnylam Pharmaceuticals by 9.8% during the first quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock worth $475,353,000 after purchasing an additional 156,411 shares during the period. Aberdeen Group plc raised its stake in Alnylam Pharmaceuticals by 12.9% during the first quarter. Aberdeen Group plc now owns 215,385 shares of the biopharmaceutical company's stock worth $57,054,000 after purchasing an additional 24,544 shares during the period. Liontrust Investment Partners LLP raised its stake in Alnylam Pharmaceuticals by 34.6% during the first quarter. Liontrust Investment Partners LLP now owns 18,880 shares of the biopharmaceutical company's stock worth $5,098,000 after purchasing an additional 4,857 shares during the period. E Fund Management Co. Ltd. raised its stake in Alnylam Pharmaceuticals by 3.4% during the first quarter. E Fund Management Co. Ltd. now owns 12,708 shares of the biopharmaceutical company's stock worth $3,431,000 after purchasing an additional 413 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its stake in Alnylam Pharmaceuticals by 3,762.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 618 shares of the biopharmaceutical company's stock worth $167,000 after purchasing an additional 602 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALNY has been the topic of a number of analyst reports. Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a research note on Monday, August 4th. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. JPMorgan Chase & Co. boosted their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Finally, Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $405.33.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the sale, the executive vice president owned 20,221 shares of the company's stock, valued at $9,269,508.61. This trade represents a 6.71% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 76,891 shares of company stock valued at $31,456,338. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded down $4.14 on Friday, hitting $448.19. The company's stock had a trading volume of 408,527 shares, compared to its average volume of 956,219. The firm has a 50 day moving average of $371.83 and a two-hundred day moving average of $301.51. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $469.81. The stock has a market cap of $58.75 billion, a price-to-earnings ratio of -181.26 and a beta of 0.25. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the prior year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.